ERROR CORRECTION FORM

Sequence Number: | CIBMTR Recipient ID: | Initials:

Today's Date: Month / Day / 20 Year | Infusion Date: Month / Day / 20 Year | CIBMTR Center Number:

Form 2565 R1.0: Sanofi Mozobil Supplemental Data Collection

Center: CRID:

Key Fields — Questions: -

Sequence Number: _____

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Event date: __ __ __ __ - __ __- __ __

Mobilization — Questions: 1 - 3

1 Did the recipient stay at a temporary location closer to the collection center for mobilization? (e.g. hotel)

○ Yes ○ No

2 Specify number of days: _____

Indicate the intended method of mobilization for the recipient. If at the time of mobilization the method was modified or an alternate method was used, report the actual method of mobilization in the Mobilization Agents section.

3 What was the intended method of stem cell mobilization for this recipient?

- ○ Mobilization with G-CSF alone (including biosimilars or peg-filgrastim) (plerixafor NOT used during initial mobilization attempt with G-CSF alone)
- ○ Mobilization with G-CSF + routine plerixafor (plerixafor used in all myeloma patients)
- ○ Mobilization with G-CSF + as needed plerixafor rescue (plerixafor given only if patients met criteria for mobilization failure)
- ○ Chemomobilization

Pre-Collection Therapy Given to Enhance Product Collection — Questions: 4 - 57

4 Was pre-collection chemotherapy given to enhance product collection?

○ Yes ○ No

5 Specify where chemotherapy was administered

○ Inpatient ○ Outpatient

6 Did the recipient receive antibacterial drugs(s) for infection prophylaxis during chemomobilization?

○ Yes ○ No

Antibiotic Prophylaxis (1) — Questions: 7 - 11

7 Specify antibiotic

- ○ Amoxicillin clavulanate oral (Augmentin)
- ○ Cefdinir oral (Omnicef)
- ○ Cefpodoxime oral (Vantin)
- ○ Ciprofloxacin IV or oral (Cipro)
- ○ Ertapenem IV
- ○ Levofloxacin IV or oral (Levaquin)
- ○ Moxifloxacin IV or oral (Avelox)
- ○ Vancomycin IV
- ○ Other antibacterial drug

8 Specify other antibacterial drug: _____

9 Total daily dose: _____ mg

10 Date started: __ __ __ __ - __ __- __ __

11 Date stopped: __ __ __ __ - __ __- __ __

12 Why was chemotherapy used for mobilization?

- ○ Center's standard mobilization approach
- ○ Treatment of primary disease
- ○ Indicated as part of a clinical trial
- ○ Other

13 Specify the ClinicalTrials.gov identification number: _____

14 Specify other reason for which chemotherapy was used for mobilization: _____

Mail, fax or email this form to Minneapolis. Fax: 612-627-5895. Email: scanform@nmdp.org.
Retain the original form at the transplant center.

ERROR CORRECTION FORM

Sequence Number: | CIBMTR Recipient ID: | Initials:

Today's Date: Month Day 20 Year | Infusion Date: Month Day 20 Year | CIBMTR Center Number:

Form 2565 R1.0: Sanofi Mozobil Supplemental Data Collection

Center: CRID:

Specify chemotherapy agents given:

15 Cyclophosphamide (Cytoxan)
yes no

16 Total daily dose: _____ mg
17 Number of days: _____
18 Date started: __ __ __ __ - __ __- __ __

Indicate if mesna was given with cyclophosphamide:

19 Mesna
Yes No

20 Total daily dose: _____ mg
21 Number of days: _____
22 Date started: __ __ __ __ - __ __- __ __

23 DPACE / DCEP (dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide / dexamethasone, cyclophosphamide, etoposide, cisplatin)
Yes No

Specify the dose, number of days, and start date for each drug:

Dexamethasone (given as part of DPACE / DCEP)

24 Total daily dose: (Dexamethasone) _____ mg
25 Number of days: _____
26 Date started: __ __ __ __ - __ __- __ __

Cisplatin (given as part of DPACE / DCEP)

27 Total daily dose: (Cisplatin) _____ mg
28 Number of days: _____
29 Date started: __ __ __ __ - __ __- __ __

Doxorubicin (given as part of DPACE / DCEP)

30 Total daily dose: (Doxorubicin) _____ mg
31 Number of days: _____
32 Date started: __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan) (given as part of DPACE / DCEP)

33 Total daily dose: (Cyclophosphamide) _____ mg
34 Number of days: _____
35 Date started: __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid) (given as part of DPACE / DCEP)

36 Total daily dose: (Etoposide) _____ mg
37 Number of days: _____
38 Date started: __ __ __ __ - __ __- __ __

39 Etoposide (VP-16, VePesid)
yes no

40 Total daily dose: _____ mg
41 Number of days: _____
42 Date started: __ __ __ __ - __ __- __ __

43 Other drug
yes no

44 Total daily dose: _____ mg
45 Number of days: _____
46 Date started: __ __ __ __ - __ __- __ __
47 Specify other drug: _____

48 Were there complications from chemotherapy?
Yes No

ERROR CORRECTION FORM

Sequence Number: | CIBMTR Recipient ID: | Initials:

Today's Date: Month Day 20 Year | Infusion Date: Month Day 20 Year | CIBMTR Center Number:

Form 2565 R1.0: Sanofi Mozobil Supplemental Data Collection

Center: CRID:

49 Specify complications from chemotherapy (check all that apply)

- ☐ Hospitalization (post-chemotherapy administration)
- ☐ Infection
- ☐ Non-neutropenic fever
- ☐ Neutropenic fever
- ☐ Nausea
- ☐ Vomiting
- ☐ Anemia requiring blood transfusion(s)
- ☐ Thrombocytopenia requiring platelet transfusion(s)
- ☐ Hypocalcemia
- ☐ Bleeding
- ☐ Other

50 Specify reason for admission: _____

51 Specify date of admission: __ __ __ __ - __ __- __ __

52 Was the recipient discharged prior to conditioning?

○ Yes ○ No

53 Specify date of discharge: __ __ __ __ - __ __- __ __

54 Specify where the recipient was hospitalized

○ Transplant center ○ Local hospital

55 Specify number of units transfused: (blood) _____

56 Specify number of units transfused: (platelets) _____

57 Specify other complication: _____

Mobilization Agents

Questions: 58 - 79

Specify mobilization agents used:

58 G-CSF

○ yes ○ no

G-CSF Types (1)

Questions: 59 - 63

59 Specify type of G-CSF

- ○ Filgrastim
- ○ Peg-filgrastim
- ○ Filgrastim-sndz (Zarxio)
- ○ TBO filgrastim (Granix)
- ○ Other

60 Specify other type of G-CSF: _____

61 Total daily dose: _____ mg

62 Number of days: _____

63 Date started: __ __ __ __ - __ __- __ __

64 Plerixafor (Mozobil)

○ yes ○ no

65 Total daily dose: _____ mg

66 Number of days: _____

67 Date started: __ __ __ __ - __ __- __ __

68 Indicate the reason for which plerixafor was given

- ○ Planned per protocol
- ○ Recipient at risk of mobilization failure

Mail, fax or email this form to Minneapolis. Fax: 612-627-5895. Email: scanform@nmdp.org.
Retain the original form at the transplant center.

ERROR CORRECTION FORM

Sequence Number: | CIBMTR Recipient ID: | Initials:

Today's Date: Month Day Year | Infusion Date: Month Day Year | CIBMTR Center Number:

Form 2565 R1.0: Sanofi Mozobil Supplemental Data Collection

Center: CRID:

69 Specify the reason recipient was at risk of mobilization failure

- Low peripheral blood CD34 count
- Low collection on day 1
- Low collection on days 1 and 2
- Other reason

70 Specify other reason: _____

71 Other mobilization agent

Yes No

72 Specify other mobilization agent: _____

73 Total daily dose: _____ mg

74 Number of days: _____

75 Date started: __ __ __ __ - __ __- __ __

76 Did the recipient receive blood transfusions (RBCs) during this apheresis collection?

Yes No

77 Specify number of units: _____

78 Did the recipient receive platelets during this apheresis collection?

Yes No

79 Specify number of units: _____

Apheresis Collection — Questions: 80 - 102

80 Was peripheral blood CD34+ checked the day prior to collection?

Yes No

81 _____ cells/µL

82 Specify the total number of apheresis collection days for this mobilization: _____

83 Was there a planned hospitalization for collection?

Yes No

84 Number of days: _____

Day of Collection (1) — Questions: 85 - 99

85 Date of collection: __ __ __ __ - __ __- __ __

86 Was apheresis collection performed on a weekend?

Yes No

87 Was there central venous access during collection? (i.e. central venous line (CVL))

yes no

88 Specify the type of central venous access

- Planned temporary CVL (for collection)
- Permanent CVL (in place and used for transplant)
- Unplanned CVL (placed after beginning collection)

89 Was the CVL removed after collection but prior to transplant?

Yes No

Labs on this date of collection:

90 Peripheral blood CD34+ cells

Known Unknown

91 _____ cells/µL

92 Absolute neutrophil count (ANC)

Known Unknown

93 _____

- x 10^9/L (x 10^3/mm^3)
- x 10^6/L

94 Platelets

Known Unknown

Mail, fax or email this form to Minneapolis. Fax: 612-627-5895. Email: scanform@nmdp.org.
Retain the original form at the transplant center.

ERROR CORRECTION FORM

Sequence Number: | CIBMTR Recipient ID: | Initials:

Today's Date: Month Day 20 Year | Infusion Date: Month Day 20 Year | CIBMTR Center Number:

Form 2565 R1.0: Sanofi Mozobil Supplemental Data Collection

Center: CRID:

95 _____ ○ x 10^9/L (x 10^3/mm^3) ○ x 10^6/L

96 Were platelets transfused ≤ 7 days before date of test?
○ Yes ○ No

97 Blood volume processed
○ Known ○ Unknown

98 Total blood volume processed on this day of collection: _____ ○ Blood volumes ○ Liters

Specify the total number of CD34+ cells collected on this date of collection:

99 Total CD34+ collected: (on this day of collection) _____ cells/kg

100 Number of bags cryopreserved: _____

101 Was this mobilization episode considered successful?
○ Yes ○ No

102 Was remobilization done as a result?
○ Yes ○ No

First Name: _____ Last Name: _____

E-mail address: _____ Date: __ __ __ __ - __ __ - __ __

Mail, fax or email this form to Minneapolis. Fax: 612-627-5895. Email: scanform@nmdp.org.
Retain the original form at the transplant center.